Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.
Incyte Genomics Inc (INCY) has a market cap of $19.44B with year-over-year revenue growth of +21.2%. Net margin stands at 25.0%. The stock trades at a P/E ratio of 15.1.
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, INCY posted revenue growth of +21.2% and trades at a P/E of 15.1.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.